FDA grants priority review for Exelixis ’ Cabometyx to treat advanced RCC

The US Food and Drug Administration (FDA) has granted a priority review for the US-based drug discovery company Exelixis ’ supplemental new drug application (sNDA) for cabometyx (cabozantinib) to treat patients with previously untreated advanced renal…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news